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Introduction
Allergological risk has gained in the recent years an ever-increasing 
importance in professional respiratory disease; substances capable 
of causing allergic respiratory diseases are more numerous than 
those that can cause pneumoconiosis, thus leading to bronchial 
asthma, the most fearsome professional respiratory disease.1-3 As a 
result, the interest of occupational medicine has also increased for 
work-related allergic rhinitis (WRAR), an entity which was con-
sidered to be of little clinical interest in the past.4-6 
WRAR is a chronic inflammatory disease of the upper re-
spiratory tract with allergic basis characterized by persistent or 
recurrent symptoms such as itching, sneezing, and nasal con-
gestion and anterior rhinorrhea, and can be associates to other 
respiratory illnesses, such as inflammation of paranasal sinuses, 
olfactory disorders, bronchial asthma,7,8 and other generic clini-
cal conditions, such as headaches or conjunctivitis. In WRAR, 
symptoms occur only after exposure to specific factors in the 
working environment and significantly affect the quality of life 
and work performance of workers.5-7 In many cases, WRAR pre-
cedes or accompanies the onset of bronchial hyper responsive-
ness, and acts as the first indicator of an allergy in the respiratory 
system. This allows workers to notice the first symptoms of al-
lergic rhinitis from a particular working environment before the 
onset of professional bronchial asthma.9-11
This work is aimed at providing an update on epidemiolo-
gy, pathogenesis, clinical symptoms, diagnosis and treatment of 
WRAR, also presenting a personal case series on 1402 patients.
Epidemiology
The burden of rhinitis in the adult population is estimated be-
tween 10 and 30%.12-14 The International Study on Asthma and 
Allergies in Childhood (ISAAC) showed a prevalence in children 
between 0.8% and 14.9% in 6-7 year olds and between 1.4% 
and 39.7% in 13-14 year olds.15 There is no equivalent to ISAAC 
for adults; national surveys show prevalence rates of rhinitis of 
between 5.9% and 29% with a mean of 16%. Perennial rhinitis is 
probably more common in adults than in children.12-14 
The overall incidence of professional rhinitis has been esti-
mated on about 7-12% of the general working population;4-6 ac-
cording to Siracusa, WRAR has an incidence of 2-87% of work-
ers exposed to high-molecular weight agents (HMW) and 3-48% 
of workers exposed to low-molecular weight agents (LMW).16 
However, overall prevalence of rhinitis related to workspace if 
probably underestimated due to the heterogeneous diagnostic cri-
teria used by different researchers.17 
Pathophysiological Mechanisms
The pathophysiological mechanisms underlying allergic rhini-
tis are started by an inflammatory response in the nasal mucosa 
composed of a rapid immunoglobulin-E(IgE)-mediated mast cell 
response followed by a late-phase response in which eosinophils, 
basophils and T cells play a central role. Involved T cells have 
been shown to express a Th2 cytokine profile with interleukin 
(IL)-4 and IL-5; cytokines regulating the Th2 response have been 
recently shown in the allergic rhinitis pathogenic mechanisms.18
Allergens at the basis of WRAR can be divided into HMW 
and LMW agents. The former are more relevant in WRAR as 
their pathophysiologic mechanisms are based on the capacity 
of agents to induce immune responses through IgE dependent 
reactions. LMW agents’ mechanisms of action are less known 
and have been shown to induce allergic response through oth-
er mechanisms such as non-immunomediated degranulation of 
mast cells.3,8,18 High and Low-molecular weight occupational 
agents that may induce WRAR are listed in Table 1.
There are many humoral and cellular immune mechanisms 
in the background of WRAR, which are caused by exposure to 
allergens in the work environment and lead to specific hypersen-
sitivity. Symptoms usually appear after latency in predisposed 
individuals and return after each subsequent exposure or persist 
continuously, depending on the frequency of exposure.19,20
The latency between initial exposure and first symptoms of 
WRAR has been reported to range from 1 month to 18 years, with 
an average of 2-3 years.21 When sensitized, nasal symptoms occur 
within minutes after exposure for HMW allergens and to up to 
several hours for LMW allergens.7 The development of WRAR is 
dependent on the level and duration of exposure to allergens.22
Clinical Symptoms
WRAR symptoms are the same of non-work related allergic rhi-
nitis, and include nasal mucus, rhinorrhea, cough, pruritus and 
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reduced nasal flows following exposure to allergens. A reduc-
tion of the sense of smell has also been often reported in WRAR 
with high impact on quality of life (QoL), although very little 
has been published about the combination of olfactory impair-
ment, allergic rhinitis and QoL.23 Symptoms can be worsened in 
a workplace environment by a variety of irritating factors, such as 
chemical vapors, dust, fluids and non-physiologic environmental 
temperature exposure.4,5,21 
The development of WRAR is also linked to the duration and 
magnitude of exposure to allergens, mostly HMW; such aller-
gens, although may be present also outside the working envi-
ronment, have a much higher concentration in working environ-
ments.4,6,7,16 Symptoms are also related to individual factors such 
as sex and age.24 Atopy is the main factor playing a role in indi-
vidual responsiveness to allergen exposure, and acts as a predis-
posing factor toward developing certain allergic hypersensitivity 
reactions; most reports refer to the role of atopy as a risk factor 
for the development of occupational asthma mainly in terms of 
exposure to HMW. Its association with the development of oc-
cupational rhinitis has been demonstrated in several studies.24-29
Unrecognized occupational exposure may lead to resistance 
to treatment and to development of complications such as nasal 
polyposis, middle ear chronic diseases, lower respiratory tract in-
fections, and sleep disorders.16,30-33 
The Association with Asthma
A strong association has been demonstrated between WRAR and 
occupational asthma (OA).9-11,34,35 Many authors have shown that 
rhinitis is an independent risk factor for bronchial asthma in both 
atopic and non-atopic individuals, and that asthma risk increases 
with duration and symptom severity.10,27,28,36 Data from the litera-
ture indicate that the number of WRAR cases is 2-4 times greater 
than OA;21 Malo reported that most patients diagnosed with OA 
also suffer from occupational rhinitis; the prevalence of symp-
toms was not different for HMW and LMW agents, although rhi-
nitis was more intense for HMW than for LMW.37 
Other studies confirm that the presence of WRAR increases 
the risk of developing OA; the importance of this association is 
in early diagnosis and prevention of secondary OA.9,34,35 A pro-
spective study on natural history after professional rhinitis by 
Karjalainen showed that during the 12-year follow-up, 11.6% of 
the patients with established work-related rhinitis developed OA, 
compared to 3.1% of the control group.38 
Diagnosis 
The diagnosis of WRAR is based on the demonstration of typical 
rhinitis symptoms that are exacerbated in the workplace environ-
ment, thus proving its association with occupational exposure, 
and excluding other conditions that may produce similar symp-
toms. Diagnosis is based on anamnestic interview, workplace 
environment study, clinical and instrumental examination, nasal 
cytology, and specific allergological tests.1,3,5 
Anamnesis and workplace examination include analysis of 
medical documentation and interview with patient and, possibly, 
employer, with the aim to investigate individual medical history 
and timing and degree of exposure.5,39 
Nasal examination includes rhinoscopy, with assessment of 
nasal septum and mucous membranes, evaluating macroscopic 
changes in the nasal mucosa and, especially, in the lower turbi-
nate area. Instrumental evaluation of nasal flows should be per-
formed through rhinomanometry, to assess nasal resistances and 
air flow volumes.40-42
Nasal cytology has a role in determination of allergic nature 
of a rhinitis, assessing the presence of inflammatory cells and 
markers within the nasal mucosa and its secretions;43-46 however, 
alterations in cytology may be present in non-allergic conditions 
causing nasal inflammation.44
Testing for reaction to specific allergens can be helpful in 
confirming the diagnosis of allergic rhinitis and in the determina-
tion of specific allergic triggers.5,17,42 Allergy skin tests are an in 
vivo method to determine immediate IgE-mediated hypersensi-
tivity to specific allergens.47-50 
Table 1. High and Low-molecular weight occupational agents that may induce allergic rhinitis (adapted from EAACI Task Force on 
Occupational Rhinitis Position Paper)
Agents Occupation
High molecular weight agents
Laboratory animals Laboratory workers
Animal-derived allergens Swine confinement workers
Insects and mites Laboratory workers, farm workers
Grain dust Grain elevators
Flour Bakers
Latex Hospital workers, textile factory workers
Other plant allergens Tobacco, carpet, hot pepper, tea, coffee, cocoa, dried fruit and saffron workers 
Biological enzymes Pharmaceutical and detergent industries workers
Fish and seafood proteins Trout, prawn, shrimp, crab and clam workers; aquarists and fish-food factory workers
Low molecular weight agents
Diisocyanates Painters, urethane mould workers
Anhydrides Epoxy resin production, chemical workers, electric condenser workers
Wood dust Carpentry and furniture making workers
Metals (platinum) Platinum refinery workers
Chemicals Reactive dye, synthetic fiber, cotton, persulphate, hairdressing, pulp and paper, shoe 
manufacturing workers
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In vitro allergy tests allow measurement of the amount of spe-
cific IgE to individual allergens in a blood sample, correlating the 
amount of specific IgE produced to a particular allergen to the 
allergic sensitivity to that factor. The measurement of the total 
level of IgE in the blood is neither sensitive nor specific for aller-
gic rhinitis.22,48,51,52 Immunological tests are part of the diagnostic 
procedure for WRAR, although may return false positive results 
and, as previously stated, are not unique indicators of the work-
place exposure to allergens.40,53-55 Serum IgE assay is a relevant 
test in allergy examination; however, the results from previous 
studies showed no significant differences in allergen-specific IgE 
concentrations in workers compared to controls who were not 
previously exposed to organic dust. Therefore, allergen molecu-
lar diagnostics may represent a useful test in allergy diagnostic 
process, but deserves caution in particular circumstances.2,40,53-58
Inhaled or intranasal tests using professional allergens are 
the gold standard in WRAR diagnosis. They can be performed 
at work or in laboratory and represent an objective method for 
assessing the presence of WRAR and the type of allergen at its 
base.1,5,13,49
Treatment
The most effective therapy for WRAR is avoidance or reduction 
of exposure by workers to allergens that have caused it. This 
can be accomplished through workplace interventions, such as 
replacement of causative substances, the use of environment ven-
tilation and personal protective equipment, and changing work-
er’s duties. Also, a role is played by education of employees and 
employers.2,18,40,59,60
Pharmacological treatment is no different from that of 
non-professional allergic rhinitis17,60 and should be complemen-
tary to workplace intervention. Pharmacotherapy is based on the 
administration of antihistamines and on the use of nasal cortico-
steroids, and only in the most serious cases, of systemic cortico-
steroid cycles.
The specific immunotherapy, commonly used in allergic rhi-
nitis, is only indicated in certain types of WRAR such as allergy 
to laboratory animals.61-64
Our Clinical Experience
We conducted a retrospective analysis on 1402 consecutive pa-
tients presenting to the Otolaryngology service of the S. Eugenio 
Hospital in Rome, Italy from July 2005 to July 2016 with a di-
agnosis of allergic rhinitis. The diagnostic protocol included an 
accurate history, physical examination and rhinoscopy with the 
use of nasal fibroscopy, and skin allergy tests and of the stop-re-
covery test in case of negativity of previous tests.
Out of 1402 cases with a diagnosis of allergic rhinitis, 381 
(27.2%) were found to have a correlation with workplace envi-
ronment allergens, thus were related to occupational activity and 
diagnosed with WRAR. Occupational categories mostly repre-
sented among WRAR patients are listed in Table 2. In details, 
the sample included 142 (37.4%) employees in the food industry 
(food, catering, mill workers, bakers, pastry makers); 57 (15.1%) 
woodworkers (industry and crafts); 46 (12.2%) employees in the 
health and pharmaceutical sector; 42 (11.1%) cosmetics (indus-
try, hairdressers, aesthetics); 39 (10.1%) agriculture and flori-
culture (production and sales); 40 (10.2%) veterinarians, and 15 
(3.9%) bodyworkers and varnishing machines. 
Conclusions
Prevention is the key element in WRAR, including a range of 
pro-therapeutic activities at both the primary and secondary pre-
vention stages. These should include interventions aimed to re-
duce the level of exposure of workers to etiologic factors, such 
as environmental changes in the workplace, the use of appropri-
ate protective equipment, and the information among employees 
about presence, symptoms and risks of WRAR. Medical surveil-
lance to determine the individual risk factors for development 
of WRAR should be considered. The most effective therapy of 
WRAR is avoidance or reduction of exposure by workers to al-
lergens that have caused it. 
Another aspect worth investigation is assessment of QoL in 
WRAR. It has been proved that the QoL deteriorates after, for ex-
ample, the onset of a loss of smell that often follows WRAR, and 
this include adverse effects on appreciation of food, interference 
with daily routine, physical health, profession, emotional stabil-
ity, leisure and a general worsening in well-being. Very little has 
been published about the combination of olfactory impairment, 
allergic rhinitis and QoL; this encourages further studies in the 
field especially focusing on WRAR.
It is therefore important to adequately assess, communicate 
and manage risks in occupational chemical exposure settings 
with the aim to protect workers and the necessity to introduce 
periodic health examinations programs focusing on workers to 
monitor health and well-being and improve working conditions 
and the working environment.
Disclosures
The following paper has been presented as a poster (Poster 2.13) 
to the 1st Scientific International Conference on CBRNe.
Table 2. Occupational categories mostly represented among 
381 WRAR patients in our case series.
Type of job
Prevalence of allergic 
rhinitis
Food industry workers Food industry workers
Woodworkers Woodworkers
Workers in the health and 
pharmaceutical sectors
Workers in the health and 
pharmaceutical sectors
Cosmetic and aesthetic 
workers
Cosmetic and aesthetic workers
Agriculture and floriculture Agriculture and floriculture
Livestock farmers and 
veterinarians
Livestock farmers and 
veterinarians
Car workers and varnishing 
machines
Car workers and varnishing 
machines
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